Development of an immune-armed therapeutic adenoviral platform for pediatric brain tumors

The POPCORN project aims to develop an innovative oncolytic virus platform that enhances anti-tumor immune responses for treating aggressive pediatric brain tumors, improving survival rates and quality of life.

Subsidie
€ 150.000
2025

Projectdetails

Introduction

Diffuse Midline Gliomas (DMGs) are the most aggressive pediatric brain tumors in desperate need of curative treatment. The median life expectancy of these children remains below 14 months after diagnosis, and nearly none survive beyond the second year.

Challenges in Treatment

Similarly, for other high-risk pediatric brain tumors, there is hardly any option after recurrence, and long-term survivors are faced with life-long sequelae that impact their quality of life. In this scenario, there is an urgent need for innovative, efficacious, and safe therapies for these patients.

Oncolytic Viruses as a Solution

Oncolytic viruses are promising anticancer biotherapeutic agents that offer a unique combination of safety profile, direct antineoplastic activity, and the induction of anti-tumor immune responses. Recently, a Phase I clinical trial showed that combining the oncolytic adenovirus Delta-24-RGD and radiotherapy is non-toxic and results in anti-tumor responses and prolonged median overall survival (17.8 months) in patients.

Limitations of Current Approaches

However, results are still insufficient to be curative due to counteracting mechanisms intrinsic to the tumor microenvironment and also triggered by the virus that eventually exceeds its immunostimulatory properties.

Proposed Technology: POPCORN

The proposed technology, termed “POPCORN,” is an oncolytic-based platform capable of expressing immunomodulatory single-domain antibodies directed to intrinsic targets in these tumors.

Development Plan

We will develop the POPCORN Proof of Concept using a state-of-the-art experimental approach and validate its safety and efficacy in vitro and relevant in vivo DMG models.

IND-Enabling Studies

We will also perform IND-enabling studies and apply for PUMA/PRIME designation.

Intellectual Property and Commercialization

Additionally, we will work on the IPR strategy, and a value proposition to develop and commercialize the POPCORN platform will be generated.

Vision for the Future

We envision the POPCORN platform becoming a game changer in treating DMGs, providing a one-of-a-kind tool for eliminating these aggressive tumors that could be extensive to other difficult-to-treat pediatric brain tumors.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-5-2025
Einddatum31-10-2026
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • UNIVERSIDAD DE NAVARRApenvoerder

Land(en)

Spain

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

ERC STG

Multimodal “4D”-therapy of pediatric high grade glioma

This project aims to develop a novel multimodal treatment strategy for pediatric high-grade glioma by combining targeted therapies, gene therapy, and CAR-T cells to improve patient outcomes.

€ 1.493.711
ERC STG

Leveraging Polymer Therapeutics as Nanomedicine for Local Glioblastoma Immunotherapy

GLIOMERS aims to develop a brain-penetrating polymeric drug delivery system to enhance immunotherapy efficacy for glioblastoma by localizing treatment and stimulating antitumor immunity.

€ 1.498.175
EIC Accelerator

A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach

TUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M.

€ 2.462.533
MIT Haalbaarheid

Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker

AdjuTec-Therapeutics ontwikkelt een gepersonaliseerde immunotherapie, PanCaVax, voor alvleesklierkanker om de overlevingskansen van patiënten na operatie te verbeteren en streeft naar OD-status voor versnelde registratie.

€ 20.000